Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
Status:
Not yet recruiting
Trial end date:
2025-09-25
Target enrollment:
Participant gender:
Summary
This is a prospective, Two-arm, comparative, randomized, controlled phase II trial, to
explore the efficacy and safety of Regorafenib and HAIC vs. FOLFOX as Second Line Therapy for
Advanced Intrahepatic Cholangiocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital